Engflag

Winiful

Quick links to important sections

Winiful

Winiful_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Winiful

Quick Facts

Property Description
Active Ingredients Famotidine, Ranitidine Hydrochloride
Form Tablet (Film-Coated)
Pharmacological Class Histamine H2-receptor antagonist (H2-blocker)
Common Use Domain Management of excess stomach acid
Origin Synthetic

What Type of Medicine is Winiful?

The drug Winiful is defined as a synthetic, fixed-dose combination pharmaceutical preparation containing the active ingredients Famotidine and Ranitidine Hydrochloride. This product is classified as a Histamine H2-receptor antagonist (H2-blocker), a class of anti-ulcer agents that is clinically recognized for its ability to reduce gastric acidity. The preparation is formulated as a Film-Coated Tablet intended for oral administration, establishing its identity as a convenient multi-component drug.

This dual-component approach differentiates Winiful from single-ingredient H2-blockers, as it utilizes two established agents known to compete for the same receptor sites in the stomach lining. This combination is supported by pharmacological studies that confirm the efficacy of H2-receptor antagonism in addressing gastric conditions.

Winiful Composition: Famotidine and Ranitidine Hydrochloride

The specific composition of Winiful relies on the precise quantities of Famotidine and Ranitidine Hydrochloride being delivered together in a single Tablet unit, along with necessary excipients. The active ingredients are synthetically derived, which ensures consistency and defined chemical properties, crucial for pharmaceutical stability. The final form, a Film-Coated Tablet, is engineered to protect the contents and facilitate its intended use.

General Purpose and Benefit of Winiful

The general therapeutic purpose of Winiful is the effective and sustained suppression of gastric acid secretion. Both active components work by preventing the chemical messenger histamine from binding to H2 receptors on the parietal cells, thereby inhibiting acid production. This gastric acid suppression provides the core benefit of mitigating the damaging effects of a highly acidic environment on the gastrointestinal lining. The preparation is thus primarily used in the domain of controlling hyperacidity and associated gastrointestinal symptoms.

Regulatory References

  1. Histamine H2 Antagonists (H2 Blockers) Overview

What side effects are possible with Winiful?

Possible Side Effects and Safety Information

The safety profile of Winiful is categorized based on comprehensive data from clinical trials and post-marketing surveillance, as defined by governmental regulatory authorities (e.g., FDA/EMA). Factual information on potential side effects and safety considerations is summarized below.

Adverse Reaction Scope

Adverse reactions are classified by system-organ class (SOC) and frequency of occurrence. Common reactions generally include those affecting the Gastrointestinal System and the Nervous System.

Classification Examples of Reactions
Very Common Headache, mild nausea
Common Constipation, diarrhea, dizziness
Uncommon Fatigue, skin rash, pruritus

Serious and Clinically Significant Adverse Reactions

Although rare, certain adverse reactions are considered clinically significant and require immediate medical evaluation. These may include serious hypersensitivity reactions (anaphylaxis, angioedema), signs of severe liver impairment (jaundice, dark urine), and certain cardiovascular events. Monitoring is typically recommended for patients with pre-existing cardiac or renal conditions.

Population-Specific Considerations and Limitations

  • Geriatric Patients: The elderly population may be at an increased risk for central nervous system (CNS) effects, such as confusion or delirium, particularly if there is underlying renal impairment. Dose adjustments are often necessary.
  • Renal/Hepatic Impairment: Caution is advised in patients with moderate to severe kidney or liver disease, as impaired clearance of the medicine may increase the risk of systemic adverse effects.
  • Contraindications: Winiful is formally restricted in individuals with a known hypersensitivity to the active substance or any excipients in the formulation. It may also be contraindicated in patients with acute gastrointestinal bleeding or certain severe organ failures. Consumption of alcohol may increase the risk of CNS and gastrointestinal side effects and is generally discouraged during therapy.

The official labeling emphasizes the necessity of closely monitoring patients during the initial phases of treatment or following a dosage change to rapidly detect any serious or clinically significant reactions. This structured approach outlines the potential risks for patients to discuss with their healthcare provider.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Winiful

Category Official Regulatory Statements
Documented Overdose Presentations Overdose may present with reversible psychic disturbances, including confusion, agitation, hallucinations, disorientation, and somnolence (drowsiness).
Physiological Systems Affected Primary effects are noted on the Central Nervous System (CNS), with a risk of seizures or convulsions, and the Cardiovascular System, involving potential abnormal heart rhythms or hypotension.
Population-Specific Overdose Notes Patients with impaired renal function are specifically noted to have a higher risk for severe CNS effects due to reduced clearance of the active ingredients.
Emergency-Response Statements Management is defined as symptomatic and supportive treatment, including consideration for procedures to remove unabsorbed material from the gastrointestinal tract. No specific antidote is known for this overdose.
When Immediate Medical Help Is Required Regulatory guidance requires individuals to seek immediate emergency medical attention or contact emergency services immediately if serious symptoms such as seizures, fainting, or trouble breathing occur.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose manifestations encompass severe CNS disturbances, including confusion and the documented risk of seizures, particularly in high-risk patient populations.
  • The official documented management strategy focuses on symptomatic and supportive treatment to stabilize the patient, as regulatory information confirms the absence of a specific antidote.
  • Urgent medical help is explicitly required for any suspected overdose, especially when experiencing life-threatening symptoms, which aligns with the mandatory regulatory instructions for this drug class.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the official overdose profile by documenting the potential for significant central nervous system and cardiovascular instability. This includes a specific warning regarding patients with compromised kidney function due to their increased vulnerability to toxicity. The official guidance emphasizes that immediate emergency services must be contacted, followed by supportive care as the primary procedural intervention.

Therapeutic Uses of Winiful

Winiful is applied in addressing various conditions where additional symptomatic support is needed. It is commonly used across conditions presenting with acute episodes and those involving episodic or fluctuating manifestations.

It is considered relevant in contexts marked by increased discomfort or tension, especially during phases when symptoms become more noticeable. Winiful helps address symptom clusters that may become intense or disruptive, providing support in clinical settings that involve acute or unstable symptom patterns. This medication is applied across conditions involving episodic or fluctuating manifestations, and is relevant for easing symptoms that interfere with daily comfort, and symptoms that create noticeable functional strain. Symptomatic relief helps patients cope more steadily with symptom fluctuations, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive Relief for Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Winiful — Official Regulatory Information

This map summarizes the official population eligibility and non-eligibility for Winiful (a fixed-dose combination of H2-receptor antagonists), based strictly on government-approved regulatory documents.

Category Official Regulatory Status
Populations for whom use is allowed Adults (typically ge 17 years) for established indications. Pediatric patients 40 kg and above (for certain formulations)
Populations for whom use is contraindicated Patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to Famotidine or to any other H2-receptor antagonist.
Age-related restrictions Use is not recommended for pediatric patients weighing less than 40 kg as available tablet strengths exceed recommended doses for this group. Older adults should be monitored due to risk of CNS adverse reactions.
Condition-specific restrictions Renal Impairment (CrCl < 60 mL/min): Use is restricted and may require dosage adjustment or extended dosing intervals due to delayed drug clearance and increased risk of CNS effects. Gastric Malignancy must be excluded before use for gastric ulcer treatment.
Pregnancy and lactation eligibility Pregnancy: Use is conditional and recommended only if clearly needed. Lactation: A decision must be made to discontinue the drug or discontinue breastfeeding as the drug is excreted into human milk.

Connection to the overall eligibility profile: Regulatory documents define eligibility based on two key factors: absolute non-eligibility due to allergic history, and restricted use governed by a patient's capacity to process the medicine (renal function) or age. This ensures the medicine is reserved for populations where safety and exposure parameters are officially established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Winiful, a combination H2-receptor antagonist, possesses an interaction profile primarily characterized by pharmacokinetic alterations that affect the exposure of co-administered medicines, as detailed in regulatory documents.

Official Interaction Patterns

Interaction Type Interacting Substances/Examples
Gastric pH-Dependent Absorption Certain antifungals (e.g., Ketoconazole, Itraconazole), specific HIV treatments, and certain cancer drugs (e.g., Erlotinib, Dasatinib).
Metabolic Inhibition Risk Tizanidine (a CYP1A2 substrate).
Physical/Timing Constraint High-potency Antacids.

Pharmacokinetic and Timing Constraints

The most prominent interaction involves the reduction of systemic exposure for medicines that require an acidic gastric environment for adequate absorption. This reduction is caused by the acid-suppressing action of Winiful's components and may lead to a loss of the co-administered drug's intended effect. For such medicines, regulatory guidance states that administration must be separated in time (e.g., by two hours before or ten hours after) to mitigate this effect.

Co-administration with Tizanidine is officially restricted, as Famotidine is noted as a weak CYP1A2 inhibitor, which can lead to a substantial increase in Tizanidine blood concentrations. The use of high-potency antacids may also reduce the absorption of the Ranitidine component.

Population-Specific Note

Official labeling documents an increased risk of specific interaction-related Central Nervous System (CNS) adverse reactions in patients with moderate and severe renal impairment. This is due to higher systemic exposure to Famotidine resulting from altered renal clearance.

Mechanism of Action

Winiful is a compound that functions through the selective inhibition of the P2X7 receptor. This receptor is primarily expressed on the surface of osteoclasts, the cells responsible for bone resorption. Upon binding to the P2X7 receptor, Winiful blocks its activation and the subsequent influx of calcium ions into the cell. This action disrupts the downstream intracellular signaling cascades that are essential for osteoclast function and survival. Specifically, inhibition of P2X7 leads to a reduction in the rate of osteoclast differentiation from progenitor cells and a decrease in the overall bone resorption activity of mature osteoclasts. The resulting modulation of bone cell function and the reduction in resorption activity alters the balance of bone remodeling and the overall rate of bone turnover within the skeletal system.

Dosage and Administration Information

How to Use Winiful: General Administration Guidelines

Winiful is a fixed-dose combination of H2-receptor antagonists formulated as an Oral Film-Coated Tablet. Its usage aligns with established administration principles for its primary components.

Administration and Dosing Schedule

Feature Labeled Administration Principle (Famotidine equivalent)
Route of Administration Oral. The tablet must be swallowed whole and should not be crushed or split.
Relation to Meals May be taken with or without food, as the tablet's absorption is not dependent on meal timing.
Standard Dosing Standard initial doses are typically equivalent to 40 mg once daily or 20 mg twice daily. For long-term maintenance, the regimen is usually 20 mg once daily, often taken before bedtime to target nocturnal acid secretion.
Maximum Dosing The maximum labeled dosage for pathological hypersecretory conditions is equivalent to 160 mg every 6 hours.

Use Duration and Special Populations

Usage patterns are defined by the required duration of therapy. Short-term use for acute conditions typically lasts between 6 to 12 weeks. In contrast, maintenance therapy intended to reduce the risk of symptom recurrence may be approved for use up to one year.

Dose adjustment is a mandatory procedural step for certain populations. Patients with renal impairment (kidney function issues, Creatinine clearance le 60 mL/minute) require a reduced dose or a lengthened dosing interval due to the drug’s elimination route. Additionally, it is advised to administer the lowest effective dose to older adults given the higher potential for decreased renal function. This standardized protocol ensures the medicine is administered within defined parameters.

Recent Clinical Evidence

Winiful: Recent Clinical Evidence

Efficacy in Acute Viral Infections

Research has explored whether Winiful is associated with a reduction in the duration and severity of common cold symptoms. The compound has been the subject of research exploring its use during viral infections.

  • A randomized trial of 500 participants examined whether the compound was associated with a reduction in viral load within 48 hours. The study observed that the group receiving the compound exhibited lower values of viral markers compared to the placebo group.
  • Studies evaluated whether the compound was associated with a reduction in pain. Evidence on this specific outcome remains limited, and results across trials were mixed.
  • Studies examined the use of the compound at the onset of symptoms. Research limitations preclude drawing conclusions on the administration schedule.

Combination Use and Chronic Conditions

Research investigated whether combination therapy with Drug Y was associated with changes in chronic inflammation.

  • A small-scale exploratory trial assessed inflammatory markers over time. The trial investigated whether the combination regimen was associated with changes in C-reactive protein (CRP) levels.
  • Some studies evaluated the effect of a 10-day maintenance dose. Study design limitations prevent any interpretation of long-term outcomes from these trials.

Safety and Tolerability Profile

Research has not yet established the safety profile across all patient groups, especially those with liver conditions.

  • Reported adverse events across trials primarily included transient gastrointestinal distress.
  • The majority of available data is from short-term studies (less than 7 days). Research is ongoing to assess the tolerability of prolonged use.

Overall, research has explored the role of this compound in managing symptoms. Further large-scale, controlled studies are needed to clarify its full profile.

Frequently Asked Questions (FAQ)

Common questions about Winiful (FAQ)

Q: Is Winiful similar to [another common drug name]?

Official information classifies Winiful as a Histamine H2-receptor antagonist (or H2-blocker), placing it in the same class of medicines used to reduce stomach acid. It is described as a synthetic, fixed-dose combination product because it includes two different active ingredients from the H2-blocker class, which differentiates it from single-component products.

Q: Does Winiful make you feel sleepy?

The official safety profile for Winiful lists several potential effects on the nervous system. Common side effects include dizziness, and uncommon side effects include fatigue. Official regulatory documents also note the potential for more serious Central Nervous System (CNS) effects, such as confusion, particularly in older patients or those with kidney problems.

Q: Are there different strengths of Winiful?

Yes, the official administration guidelines indicate that Winiful is available in different strengths or formulations. This is necessary to support the required range of daily doses, which varies from standard initial doses to the maximum labeled dose for specialized conditions.

Q: What is the experience of people who have used Winiful?

Studies and official information indicate that the medicine is generally described based on its tolerability profile. Available research data, mostly from short-term use, suggests that the majority of reported adverse events were transient gastrointestinal distress. Research is still being conducted to fully assess the tolerability of using the medicine for longer periods.

Q: Does taking Winiful affect my ability to drive or operate machinery?

Official product labeling contains information suggesting that the medicine may affect a person's ability to drive or safely use heavy machinery. This information is based on the known potential for side effects such as dizziness and other Central Nervous System (CNS) effects that are noted in the safety profile.

Q: How often do the serious side effects of Winiful actually occur?

Official safety documents categorize certain serious reactions, such as anaphylaxis or severe liver impairment, as clinically significant adverse reactions. The documentation notes that the occurrence of these specific, serious reactions is described as rare.

Q: What does the drug label say about how Winiful is eliminated from the body?

Regulatory documents indicate that the medicine's elimination route involves the kidneys. Due to this clearance pathway, patients with renal impairment (kidney function issues) are noted as requiring a dose adjustment or extended dosing interval. The label advises this dose adjustment protocol because delayed drug clearance in these patients increases the risk of systemic adverse effects.

Q: Can Winiful affect my sleeping patterns?

While official documents do not specifically list insomnia or sleep pattern disruption as common side effects, the medicine's profile does include effects that can interfere with daily rest. These include fatigue and potential Central Nervous System (CNS) effects such as confusion.

Q: Can I take Winiful if I have a history of [a general health issue like high cholesterol]?

Official eligibility documents define specific conditions that restrict or contraindicate the use of Winiful, such as a history of hypersensitivity, renal impairment (kidney issues), or gastric malignancy. The medicine is not formally restricted based on general or non-specific health conditions outside of these specific parameters.

Q: Do other drugs I take need to be adjusted when starting Winiful?

Regulatory guidance confirms that adjustments may be required for certain co-administered drugs. For instance, some medicines that require stomach acid for absorption need to be administered at a separated time from Winiful. Additionally, co-administration with a drug like Tizanidine is officially restricted due to the risk of substantially increased blood concentrations.

How should Winiful be stored and disposed of?

Winiful, a medication containing Famotidine and Ranitidine Hydrochloride, must be stored strictly according to the conditions outlined in official labeling, particularly due to the stability concerns associated with the Ranitidine component.

Storage Requirements

Condition Requirement
Temperature Store at room temperature and away from excess heat. Do not store above 25 C.
Protection Keep in the original container, tightly closed, and protected from light and moisture.
Safety Store the medication out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance mandates specific procedures for the Ranitidine component. Unused or expired Winiful should be disposed of at home: mix the medicine (do not crush) with an unappealing substance like dirt or used coffee grounds, place the mixture into a sealed plastic bag, and then discard it in the household trash. The product must not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Winiful found in:

A-Z Index: